Stephen A Harrison

Summary

Affiliation: Walter Reed Army Medical Center
Country: USA

Publications

  1. doi request reprint Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA
    J Clin Gastroenterol 47:271-9. 2013
  2. doi request reprint Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Hepatology 56:464-73. 2012
  3. doi request reprint Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis
    Amalia Gastaldelli
    Diabetes Division, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Hepatology 50:1087-93. 2009
  4. doi request reprint Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study
    Daniel E Brady
    Department of Medicine, Brooke Army Medical Center, San Antonio, Texas, USA
    Clin Gastroenterol Hepatol 8:66-71.e1. 2010
  5. doi request reprint Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study
    Christopher D Williams
    Gastroenterology and Hepatology Service, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA
    Gastroenterology 140:124-31. 2011
  6. ncbi request reprint Impact of obesity on treatment of chronic hepatitis C
    Michael R Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 43:1177-86. 2006
  7. doi request reprint Review of treatment options for nonalcoholic fatty liver disease
    Richele L Corrado
    Department of Medicine, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889 5600, USA
    Med Clin North Am 98:55-72. 2014
  8. ncbi request reprint Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis
    Bogdan Balas
    Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, Room 3 380S, 7703 Floyd Curl Drive, San Antonio, TX 78284 3900, USA
    J Hepatol 47:565-70. 2007
  9. ncbi request reprint A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
    Renata Belfort
    University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    N Engl J Med 355:2297-307. 2006
  10. doi request reprint Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy
    Stephen A Harrison
    Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA
    Hepatology 52:864-74. 2010

Collaborators

Detail Information

Publications52

  1. doi request reprint Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA
    J Clin Gastroenterol 47:271-9. 2013
    ..Our aim was to determine whether SVR rates in patients with low/elevated LDL can be improved by dose intensification...
  2. doi request reprint Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Hepatology 56:464-73. 2012
    ..5 ± 1.71 and -3.7 ± 1.62 IU/mL in the pioglitazone and standard-care groups, respectively, Δ = 0.21 IU/mL, P = 0.4394)...
  3. doi request reprint Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis
    Amalia Gastaldelli
    Diabetes Division, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Hepatology 50:1087-93. 2009
    ..02 versus placebo). Adipo-IR decreased by 47% and correlated with the reduction of hepatic fat (r=0.46, P=0.009) and with the reduction in hepatic necroinflammation (r=0.47, P=0.0007)...
  4. doi request reprint Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study
    Daniel E Brady
    Department of Medicine, Brooke Army Medical Center, San Antonio, Texas, USA
    Clin Gastroenterol Hepatol 8:66-71.e1. 2010
    ..Induction therapy with higher doses of PEG interferon may improve first-phase viral kinetics and thus improve the overall SVR in genotypes 1 and 4 patients...
  5. doi request reprint Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study
    Christopher D Williams
    Gastroenterology and Hepatology Service, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA
    Gastroenterology 140:124-31. 2011
    ..Prevalence of nonalcoholic fatty liver disease (NAFLD) has not been well established. The purpose of this study was to prospectively define the prevalence of both NAFLD and nonalcoholic steatohepatitis (NASH)...
  6. ncbi request reprint Impact of obesity on treatment of chronic hepatitis C
    Michael R Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 43:1177-86. 2006
    ....
  7. doi request reprint Review of treatment options for nonalcoholic fatty liver disease
    Richele L Corrado
    Department of Medicine, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889 5600, USA
    Med Clin North Am 98:55-72. 2014
    ..1 and 2 summarize current practices for the diagnosis and treatment of NAFLD with the understanding that each patient's treatment must be customized to their comorbidities, exercise tolerance, and willingness to comply with therapy...
  8. ncbi request reprint Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis
    Bogdan Balas
    Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, Room 3 380S, 7703 Floyd Curl Drive, San Antonio, TX 78284 3900, USA
    J Hepatol 47:565-70. 2007
    ..To understand the nature of weight gain associated with pioglitazone treatment in NASH we analyzed 35 patients who completed tests for determination of whole body fat (WBF) and total body water (TBW)...
  9. ncbi request reprint A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
    Renata Belfort
    University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    N Engl J Med 355:2297-307. 2006
    ..Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus...
  10. doi request reprint Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy
    Stephen A Harrison
    Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA
    Hepatology 52:864-74. 2010
    ..6, 95% confidence interval (CI) = 1.4-1.8, P < 0.001], a low HDL level (OR = 0.5, 95% CI = 0.3-0.8, P = 0.004), and statin use (OR = 2.0, 95% CI = 1.1-3.7, P = 0.02) were independently associated with SVR...
  11. ncbi request reprint Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass
    Steven P Larson
    Division of Gastroenterology and Hepatology, Wilford Hall Medical Center, San Antonio, Texas, USA
    Clin Gastroenterol Hepatol 5:1329-32. 2007
    ..Our aim was to assess for significant regional differences in histopathology between the right and left lobes of the liver in morbidly obese patients undergoing bariatric surgery...
  12. ncbi request reprint New treatments for nonalcoholic fatty liver disease
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
    Curr Gastroenterol Rep 8:21-9. 2006
    ..Future treatment for patients failing to achieve weight loss goals is likely to consist of combination therapy targeting insulin resistance, oxidative stress, and fibrogenesis...
  13. doi request reprint Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial
    Dawn M Torres
    Division of Gastroenterology, Department of Medicine, Walter Reed Army Medical Center, Washington, DC, USA
    Hepatology 54:1631-9. 2011
    ..001). Serum aminotransferases were reduced in all three groups (P < 0.001 within treatment, P > 0.05 between groups). Metformin did not significantly mitigate weight gain (P = 0.051)...
  14. doi request reprint Nonalcoholic fatty liver disease
    Angelo H Paredes
    Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA
    Clin Liver Dis 16:397-419. 2012
    ..Although currently there are no FDA-approved treatments for NASH, a multidisciplinary approach that addresses comorbid conditions and promotes modest weight loss comprises the backbone of therapy...
  15. doi request reprint Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection
    Brad Q Starley
    Department of Medicine, Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Hepatology 51:1820-32. 2010
    ..The complications of NASH, including cirrhosis and HCC, are expected to increase with the growing epidemic of diabetes and obesity...
  16. ncbi request reprint Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery
    Kevin B Barker
    Wilford Hall Medical Center, San Antonio, Texas, USA
    Am J Gastroenterol 101:368-73. 2006
    ..Treatment options are still under investigation. The primary aim of the study was to determine whether weight loss, achieved through Roux-en-Y gastric bypass (RYGBP), improved histopathology in obese patients with biopsy proven NASH...
  17. doi request reprint Features, diagnosis, and treatment of nonalcoholic fatty liver disease
    Dawn M Torres
    Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD 20892, USA
    Clin Gastroenterol Hepatol 10:837-58. 2012
    ..S. Food and Drug Administration; multimodal approaches are being developed and becoming the standard of care. We review pathogenesis and treatment approaches for the West's largest liver-related public health concern...
  18. ncbi request reprint NASH and HCC
    John M Page
    Department of Medicine, Gastroenterology Service, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
    Clin Liver Dis 13:631-47. 2009
    ..It is increasingly recognized that non-alcoholic steatohepatitis likely accounts for a substantial portion of cryptogenic hepatocellular carcinoma...
  19. doi request reprint Effect of weight loss on nonalcoholic fatty liver disease
    Anish A Patel
    Department of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    J Clin Gastroenterol 43:970-4. 2009
    ..This review discusses dietary modification, exercise, weight loss pharmacotherapy, and surgical intervention as potential options for patients with NAFLD...
  20. doi request reprint Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil
    Dawn M Torres
    Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Washington, DC, USA
    Semin Liver Dis 32:30-8. 2012
    ..This review focuses on HCC in noncirrhotic NASH with an emphasis on clinical presentation, pathogenesis, and implications for screening...
  21. doi request reprint Diagnosis and therapy of nonalcoholic steatohepatitis
    Dawn M Torres
    Department of Gastroenterology, Fort Sam Houston, Brooke Army Medical Center, San Antonio, Texas 78234, USA
    Gastroenterology 134:1682-98. 2008
    ..Other potential therapeutic agents directed at cytoprotection or reduction of fibrosis are under investigation. This article focuses on diagnosis and therapy available and under development for this chronic liver disease...
  22. doi request reprint Insulin resistance and hepatitis C: an evolving story
    Mohammed Eslam
    Department of Medicine, Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Gut 60:1139-51. 2011
    ....
  23. doi request reprint Physical activity: an essential component of lifestyle modification in NAFLD
    Benjamin Rodriguez
    Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Washington, DC 20889, USA
    Nat Rev Gastroenterol Hepatol 9:726-31. 2012
    ..The optimal physical activity regimen in terms of both effectiveness and compliance remains to be determined and is the focus of this Review...
  24. ncbi request reprint Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease
    Nicole A Palekar
    Wilford Hall Medical Center, San Antonio, TX 78258, USA
    Liver Int 26:151-6. 2006
    ..In conclusion, we propose a noninvasive screening model for distinguishing simple steatosis from NASH. Identifying patients at risk for NASH will allow clinicians to more accurately determine who may benefit from liver biopsy...
  25. doi request reprint Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter?
    Jeremy P Domanski
    Department of Medicine, Division of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA
    J Clin Gastroenterol 46:427-30. 2012
    ..We aimed to investigate the prevalence of cardiovascular disease in patients with nonalcoholic steatohepatitis (NASH) versus non-NASH fatty liver...
  26. doi request reprint Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial
    Stephen A Harrison
    Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Hepatology 49:80-6. 2009
    ..However, subjects who lost >or=5% of body weight over 9 months improved insulin resistance and steatosis, and those subjects who lost >or=9% also achieved improved hepatic histologic changes...
  27. ncbi request reprint Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease
    Shane J Mills
    Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234 6200, USA
    Curr Gastroenterol Rep 7:32-6. 2005
    ..Although they are histologically indistinct, AFLD and NAFLD follow different clinical courses. This article compares the natural history of these diseases...
  28. pmc Benefits of lifestyle modification in NAFLD
    Stephen A Harrison
    Gastroenterology and Hepatology Division, Brooke Army Medical Center, Fort Sam, Houston, TX, USA
    Gut 56:1760-9. 2007
  29. doi request reprint NAFLD: Predictive value of ALT levels for NASH and advanced fibrosis
    Dawn M Torres
    Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889 5600, USA
    Nat Rev Gastroenterol Hepatol 10:510-1. 2013
    ..Verma et al. addressed the utility of alanine aminotransferase levels for predicting NASH or advanced fibrosis to decide who would benefit from the definitive test of liver biopsy...
  30. doi request reprint Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association?
    Ryan M Kwok
    Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Washington, DC, USA
    Hepatology 58:1166-74. 2013
    ..The epidemiologic association between VDD and NAFLD as well as the role of VDD in the pathogenesis of NAFLD and the available evidence on the clinical utility of vitamin D replacement in NAFLD populations are discussed...
  31. ncbi request reprint Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Stephen A Harrison
    Department of Gastroenterology and Hepatology, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
    Clin Liver Dis 8:861-79, ix. 2004
    ..The article includes current thoughts on the natural history and pathogenesis of NAFLD and describes current trends in the diagnosis and treatment of this condition...
  32. ncbi request reprint Pharmacologic management of nonalcoholic fatty liver disease
    Stephen A Harrison
    Brooke Army Medical Center, Department of Gastroenterology and Hepatology, 3851 Roger Brooke Drive, Ft Sam Houston, TX 78234, USA
    Clin Liver Dis 8:715-28, xii. 2004
    ..This article focuses on the various therapeutic agents that have been evaluated in the treatment of NAFLD and their efficacy as well as their limitations...
  33. doi request reprint Abnormal liver tests and fatty liver on ultrasound
    Stephen A Harrison
    Department of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA
    Clin Gastroenterol Hepatol 6:26-9. 2008
  34. doi request reprint Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, Texas 78324, USA
    Clin Gastroenterol Hepatol 6:864-76. 2008
    ..Studies are under way to determine whether improving insulin sensitivity results in better outcomes in patients receiving pegylated interferon alfa plus ribavirin therapy for chronic hepatitis C...
  35. ncbi request reprint Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis
    Stephen A Harrison
    Brooke Army Medical Center, University of Texas Health Science Center San Antonio, San Antonio, Texas, USA
    Am J Gastroenterol 98:2485-90. 2003
    ..There is currently no proven medical therapy for the treatment of NASH. The aim of our study was to evaluate the efficacy of combination alpha-tocopherol (vitamin E) and vitamin C in reducing histologic inflammation and fibrosis...
  36. ncbi request reprint Diabetic hepatosclerosis: diabetic microangiopathy of the liver
    Stephen A Harrison
    Liver Center, Department of Medicine, Saint Louis University School of Medicine, St Louis, MO 63110, USA
    Arch Pathol Lab Med 130:27-32. 2006
    ..After observing a noncirrhotic form of hepatic sinusoidal fibrosis in patients with long-standing diabetes mellitus who underwent liver biopsy, we set about to characterize this novel entity...
  37. ncbi request reprint Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related
    Paul H Hayashi
    Wilford Hall Medical Center, Gastroenterology and Pathology Departments, Brooke Army Medical Center, San Antonio, Texas, USA
    Am J Gastroenterol 99:76-81. 2004
    ..We aimed to determine the prevalence of significant alcohol intake in previously diagnosed nonalcoholic fatty liver (NAFL) patients...
  38. ncbi request reprint Steatosis and chronic hepatitis C infection: mechanisms and significance
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Clin Gastroenterol Hepatol 3:S92-6. 2005
    ....
  39. ncbi request reprint Same day endoscopy and percutaneous liver biopsy: safety and cost-effectiveness
    J Aaron Cook
    Brooke Army Medical Center, 3841 Roger Brooke Drive, Ft Sam Houston, TX 78234, USA
    Dig Dis Sci 54:1753-7. 2009
    ..001). In conclusion, endoscopy and percutaneous liver biopsy can safely be performed in the same patient on the same day, which simultaneously increases patient satisfaction and is cost-effective...
  40. ncbi request reprint Liver disease in patients with diabetes mellitus
    Stephen A Harrison
    Department of Hepatology, Brooke Army Medical Center, Fort Sam, Houston, TX, USA
    J Clin Gastroenterol 40:68-76. 2006
    ..The association with diabetes and cirrhosis, acute liver failure, hepatocellular carcinoma, and outcomes following orthotopic liver transplantation will also be discussed...
  41. doi request reprint HCV in patients with end-stage renal disease
    Emuejevoke J Okoh
    Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA
    Am J Gastroenterol 103:2123-34. 2008
    ..Finally, with regard to postrenal transplant treatment of HCV infection, there is no evidence to support treatment with interferon-based therapy and pretransplant treatment remains the best option whenever possible...
  42. doi request reprint MiraLAX is not as effective as GoLytely in bowel cleansing before screening colonoscopies
    Michael Hjelkrem
    Department of Medicine, Division of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA
    Clin Gastroenterol Hepatol 9:326-332.e1. 2011
    ....
  43. ncbi request reprint Small molecule and novel treatments for chronic hepatitis C virus infection
    Stephen A Harrison
    Brooke Army Medical Center, Division of Gastroenterology and Hepatology, Department of Medicine, Fort Sam Houston, Texas, USA
    Am J Gastroenterol 102:2332-8. 2007
    ..In conclusion, small molecule and novel therapies for HCV infection are showing promise in clinical trials, and research to develop new agents and optimize treatment regimens is ongoing...
  44. doi request reprint Nutrition in cirrhosis and chronic liver disease
    Wassem Juakiem
    Department of Medicine, San Antonio Military Medical Center, 3851 Roger Brooke Dr, 3600 Fort Sam Houston, San Antonio, TX 78234, USA
    Clin Liver Dis 18:179-90. 2014
    ..This review provides an overview of nutrition in chronic liver disease with an emphasis on its pathogenesis as well as ways to assess nutritional status and intervene in an effort to improve nutrition. ..
  45. doi request reprint Editorial: killing two birds with one stone: screening for chronic hepatitis C at the time of colonoscopy in the baby boomer cohort
    Dawn M Torres
    Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland, USA
    Am J Gastroenterol 108:990-2. 2013
    ..As gastroenterologists interface with these patients for screening colonoscopy, this represents a unique opportunity to complete this screening and identify CHC patients at risk for advanced liver disease...
  46. pmc Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease
    Nadege T Touzin
    Gastroenterology and Hepatology Service, Wilford Hall Medical Center, San Antonio, Texas, USA
    Therap Adv Gastroenterol 4:169-76. 2011
    ..However, patients with negative ultrasounds appeared to have a lower polyp burden...
  47. doi request reprint Association of serum adipocytokines with insulin resistance and liver injury in patients with chronic hepatitis C genotype 4
    Mahmoud Aboelneen Khattab
    Department of Internal Medicine, Minia University, Minia, Egypt
    J Clin Gastroenterol 46:871-9. 2012
    ..We investigated the potential role of adipocytokines in HCV-induced insulin resistance (IR) and modulating the progression of liver disease in patients with HCV-4...
  48. ncbi request reprint Current treatments in nonalcoholic steatohepatitis
    Dawn M Torres
    Stephen A Harrison, MD Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
    Curr Treat Options Gastroenterol 10:425-34. 2007
    ..Although most of these approaches have been studied as single-modality therapy, we believe that combination, multimodality therapy is required to treat this disease effectively...
  49. ncbi request reprint Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase
    Matthew W Pantsari
    Brooke Army Medical Center, San Antonio, TX, USA
    J Clin Gastroenterol 40:633-5. 2006
    ..To define a subset of patients with nonalcoholic fatty liver disease (NAFLD) with isolated elevations in alkaline phophatase...
  50. ncbi request reprint Advances in the understanding and treatment of nonalcoholic fatty liver disease
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, Missouri, USA
    Drugs 63:2379-94. 2003
    ....
  51. doi request reprint Olanzapine and benztropine as a cause of ischemic colitis in a 27-year-old man
    Stephen J Park
    Department of Medicine, Brooke Army Medical Center, San Antonio, TX, USA
    J Clin Gastroenterol 46:515-7. 2012
    ..Despite the fact that ischemic colitis is such a rare adverse effect of antipsychotic medications, it is important to consider because of its potentially fatal outcomes...
  52. ncbi request reprint Extrahepatic manifestations of hepatitis C
    Nicole A Palekar
    Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston, TX, USA
    South Med J 98:1019-23. 2005
    ..This paper serves to review the growing body of literature detailing the extrahepatic manifestations of chronic hepatitis C...